Skip to main content

Yodoxin Disease Interactions

There are 4 disease interactions with Yodoxin (iodoquinol).

Major

Iodoquinol (applies to Yodoxin) liver disease

Major Potential Hazard, High plausibility.

The use of iodoquinol is contraindicated in patients with hepatic damage. Iodoquinol is a halogenated 8-hydroxyquinolone that may have a prolonged effect in patients with liver dysfunction. High dosages of iodoquinol have been associated with optic neuritis, optic atrophy, and peripheral neuropathy.

References

  1. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
Moderate

Iodoquinol (applies to Yodoxin) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

The use of high dosages or prolonged therapy with iodoquinol has been associated with the development of peripheral neuropathy. Therapy with iodoquinol should be administered cautiously in patients with peripheral neuropathy.

References

  1. Oakley GP Jr (1973) "The neurotoxicity of the halogenated hydroxyquinolines. A commentary." JAMA, 225, p. 395-7
  2. (1974) "Warning on diiodohydroxyquin." Med Lett Drugs Ther, 16, p. 71-2
  3. American Academy of Pediatrics Committtee on Drugs (1990) "Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy." Pediatrics, 86, p. 797-8
  4. Committee on Drugs (1974) "Blindness and neuropathy from diiodohydroxyquin-like drugs." Pediatrics, 54, p. 378-9
View all 4 references
Moderate

Iodoquinol (applies to Yodoxin) visual field defects

Moderate Potential Hazard, High plausibility. Applicable conditions: Visual Defect/Disturbance

The use of iodoquinol has been associated with optic neuritis and optic atrophy when given in high dosages for prolonged periods. Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years. Visual deterioration may be irreversible. Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects. Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age. Long-term therapy should be avoided in all patients.

References

  1. Behrens MM (1974) "Letter: Optic atrophy in children after diiodohydroxyquin therapy." JAMA, 228, p. 693-4
  2. Oakley GP Jr (1973) "The neurotoxicity of the halogenated hydroxyquinolines. A commentary." JAMA, 225, p. 395-7
  3. Idriss ZH (1975) "Letter: Diiodohydroxyquin and optic atrophy." Pediatrics, 55, p. 299
  4. Fleisher DI, Hepler RS, Landau JW (1974) "Blindness during diiodohydroxyquin (Diodoquin) therapy: a case report." Pediatrics, 54, p. 106-8
  5. Pittman FE, Westphal MC (1974) "Optic atrophy following treatment with diiodohydroxyquin." Pediatrics, 54, p. 81-3
  6. American Academy of Pediatrics Committtee on Drugs (1990) "Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy." Pediatrics, 86, p. 797-8
  7. Committee on Drugs (1974) "Blindness and neuropathy from diiodohydroxyquin-like drugs." Pediatrics, 54, p. 378-9
  8. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
View all 8 references
Minor

Iodoquinol (applies to Yodoxin) thyroid disease

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Hyperthyroidism, Hypothyroidism

Protein-bound serum iodine levels may be increased during treatment with iodoquinol and may, therefore, interfere with certain thyroid function tests. Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.

References

  1. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc

Yodoxin drug interactions

There are 95 drug interactions with Yodoxin (iodoquinol).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer